Brought to you by 
Elan and RTP form joint venture to develop cyclosporine
13 Jul 1999
Executive Summary
Elan and RTP Pharma (formulations for water insoluble drugs) have formed a joint venture, The Cyclosporine Co. (TCC) to develop cyclosporine products.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- Joint Venture
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Elan and RTP form joint venture to develop cyclosporine
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice